Pharming Group N.V. (PHAR) Q3 2025 Earnings — Mixed Results

Screener

Reported November 6, 2025 · Before market open

Revenue$97.3MMiss by $932.8K

EPS$0.10Beat by $0.05

Revenue estimate$98.2M

EPS estimate$0.05

Next report

Nov 5, 2026 (in 3 months)

Revenue estimate$106.1M

EPS estimate$0.10

Versus estimates

Revenue

Q2 2026$90.2MMiss by $9.3M Q1 2026$72.4MMiss by $19.6M Q4 2025$106.5MMiss by $5.3M

Q3 2025$97.3MMiss by $932.8K

Q2 2025$110.6MBeat by $30.4M Q1 2025$86.7MBeat by $14.0M

Diluted EPS

Q2 2026$0.02Miss by $0.04 Q1 2026-$0.07Miss by $0.12 Q4 2025$0.07Miss by $0.08

Q3 2025$0.10Beat by $0.05

Q2 2025$0.06Beat by $0.16 Q1 2025-$0.22Beat by $0.03

FAQ

When did Pharming Group N.V. report Q3 2025 earnings?: Pharming Group N.V. (PHAR) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Pharming Group N.V.'s Q3 2025 revenue and EPS?: Pharming Group N.V. reported revenue of $97.3M and eps of $0.10 for Q3 2025.
Did Pharming Group N.V. beat estimates in Q3 2025?: Revenue missed the consensus estimate of $98.2M by $932.8K. EPS beat the consensus estimate of $0.05 by $0.05.
How did Pharming Group N.V.'s Q3 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 16.0% from $83.8M a year earlier.

Ask the moment Pharming Group N.V. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk